The estimated Net Worth of Christophe Queva is at least 1.68 百万$ dollars as of 1 June 2021. Dr Queva owns over 23,555 units of Oncorus stock worth over 5,739$ and over the last 4 years he sold ONCR stock worth over 1,126,465$. In addition, he makes 545,582$ as Chief Scientific Officer & Sr. VP of Research at Oncorus.
Dr has made over 5 trades of the Oncorus stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 23,555 units of ONCR stock worth 392,897$ on 1 June 2021.
The largest trade he's ever made was exercising 35,561 units of Oncorus stock on 24 May 2021 worth over 64,365$. On average, Dr trades about 13,278 units every 7 days since 2020. As of 1 June 2021 he still owns at least 47,626 units of Oncorus stock.
You can see the complete history of Dr Queva stock trades at the bottom of the page.
Dr. Christophe Queva Ph.D. is the Chief Scientific Officer & Sr. VP of Research at Oncorus.
As the Chief Scientific Officer & Sr. VP of Research of Oncorus, the total compensation of Dr D at Oncorus is 545,582$. There are 3 executives at Oncorus getting paid more, with Stephen W. Harbin having the highest compensation of 815,088$.
Dr D is 53, he's been the Chief Scientific Officer & Sr. VP of Research of Oncorus since . There are 5 older and 3 younger executives at Oncorus. The oldest executive at Oncorus, Inc. is Dr. Mitchell H. Finer Ph.D., 62, who is the Co-Founder & Non-Exec. Chairman.
Christophe's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Oncorus have traded over 1,276,271$ worth of Oncorus stock and bought 2,354,001 units worth 35,555,648$ . The most active insiders traders include Ansbert Gadicke、Luke Evnin、James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of 15,538$. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth 87,421$.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus executives and other stock owners filed with the SEC include: